Both companies may succeed in this industry.

The company got some bad news to start 2026.

Evangeline Lilly has spent over twenty years portraying iconic heroes on screen, but her most daunting challenge is currently ...

Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

Shares of GPU titan Nvidia (NASDAQ:NVDA) may have been stuck in a sideways channel for the past six months, but a lot has ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech Abivax and had no contact with U.S. pharmaceutical giant Eli Lilly, ...

Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, cash-flow-backed value. Click for my LLY update.